This article pretty well maps out BOM2:
Apabetalone decreased the risk of major cardiovascular events (MACE) and hospitalization for congestive heart failure compared with placebo among patients with diabetic CKD and recent acute coronary syndrome.
Giddy Up Don!
Koo